Special Issue "Current Evidences and New Therapeutic Frontiers in Malignant Pleural Mesothelioma"

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: 30 June 2021.

Special Issue Editors

Prof. Dr. Filippo Lococo
E-Mail Website
Guest Editor
1. Department of Thoracic Surgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
2. Università Cattolica del Sacro Cuore, Rome, Italy
Interests: pulmonary metastasectomy; malignant pleural mesothelioma; pulmonary laser resection; thymic and pleural tumors; hyperthermic intrathoracic chemotherapy (HITHOC)
Dr. Andrea Billè
E-Mail Website
Co-Guest Editor
1. Division of Cancer Studies, King's College London, Guy's Hospital, London, UK
2. Department of Thoracic Surgery, Guy's Hospital, London, UK
Interests: malignant pleural mesothelioma; pleural tumors; mini-invasive thoracic surgery; thymic tumors

Special Issue Information

Dear colleagues,

As you know, malignant pleural mesothelioma (MPM) is a very rare aggressive cancer affecting an increasing number of people worldwide.

In the last decade, the investigation of its biomolecular mechanisms have led to the definition of different types of mesothelioma on the basis of gene expression, but molecularly defined groups based on prognosis are still far from being defined.

At the same time, regardless of the treatment, long-term survival is extremely poor in MPM patients because no valid therapeutic strategies have been validated.

In particular, surgical resection for MPM is a controversial topic with no universally accepted guidelines. Similarly, the frontiers of oncology are still unexplored, with immunotherapeutic approach showing controversial results in these patients.

This Special Issue the following goals:

(1) To offer to the Readers an overview on the current therapeutic options in MPM;

(2) To analyze the pathological features, genetic profile and biomolecular mechanism of MPM;

(3) To report the new frontiers in the surgical and oncological treatment of MPM.

In this sense, all submissions addressing all of the above highlighted aspects on MPM are welcome to this Special Issue. Thus, original articles, comprehensive reviews, and expert opinions are of the utmost interest, given the expansive scope of this area.

Prof. Dr. Filippo Lococo
Dr. Andrea Billè
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • malignant pleural mesothelioma
  • pleurectomy and decortication
  • immunotherapy
  • radiotherapy

Published Papers (4 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Editorial

Jump to: Research, Review, Other

Open AccessEditorial
Malignant Pleural Mesothelioma: Time Is Running Out
J. Clin. Med. 2021, 10(4), 648; https://doi.org/10.3390/jcm10040648 - 08 Feb 2021
Viewed by 709
Abstract
Malignant pleural mesothelioma (MPM) is a rare but highly malignant disease of the pleura usually related to asbestos exposure [...] Full article

Research

Jump to: Editorial, Review, Other

Open AccessArticle
Relapse Patterns and Tailored Treatment Strategies for Malignant Pleural Mesothelioma Recurrence after Multimodality Therapy
J. Clin. Med. 2021, 10(5), 1134; https://doi.org/10.3390/jcm10051134 - 08 Mar 2021
Viewed by 452
Abstract
To date, there have been no established therapies for recurrent malignant pleural mesothelioma (MPM) after multimodality treatment. Aims of this retrospective study are to analyze the recurrence pattern, its treatment and to identify the predictors of best oncological outcomes for relapsed MPM, comparing [...] Read more.
To date, there have been no established therapies for recurrent malignant pleural mesothelioma (MPM) after multimodality treatment. Aims of this retrospective study are to analyze the recurrence pattern, its treatment and to identify the predictors of best oncological outcomes for relapsed MPM, comparing extrapleural pneumonectomy (EPP) vs. pleurectomy/decortication (PD). Study population: 94 patients with recurrence of MPM after multimodality treatment underwent macroscopic complete resection (52.1% with EPP and 47.9% with PD) between July 1994 and February 2020. Distant spread was the most frequent pattern of recurrence (71.3%), mostly in the EPP group, while the PD group showed a higher local-only failure rate. Post-recurrence treatment was administered in 86.2%, whereas best supportive care was administered in 13.8%. Median post-recurrence survival (PRS) was 12 months (EPP 14 vs. PD 8 months, p = 0.4338). At multivariate analysis, predictors of best PRS were epithelial histology (p = 0.026, HR 0.491, IC95% 0.263–0.916), local failure (p = 0.027, HR 0.707, IC95% 0.521–0.961), DFS ≥ 12 months (p = 0.006, HR 0.298, IC95% 0.137–0.812) and post-recurrence medical treatment (p = 0.046, HR 0.101, IC95% 0.897–0.936). The type of surgical intervention seems not to influence the PRS if patients are fit enough to face post-recurrence treatments. In patients with a prolonged disease-free interval, in the case of recurrence the most appropriate treatment seems to be the systemic medical therapy, even in the case of local-only relapse. Full article
Show Figures

Figure 1

Review

Jump to: Editorial, Research, Other

Open AccessReview
The Evolving Landscape of the Molecular Epidemiology of Malignant Pleural Mesothelioma
J. Clin. Med. 2021, 10(5), 1034; https://doi.org/10.3390/jcm10051034 - 03 Mar 2021
Viewed by 508
Abstract
Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy that most commonly affects the pleural lining of the lungs. It has a strong association with exposure to biopersistent fibers, mainly asbestos (80% of cases) and—in specific geographic regions—erionite, zeolites, ophiolites, and fluoro-edenite. [...] Read more.
Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy that most commonly affects the pleural lining of the lungs. It has a strong association with exposure to biopersistent fibers, mainly asbestos (80% of cases) and—in specific geographic regions—erionite, zeolites, ophiolites, and fluoro-edenite. Individuals with a chronic exposure to asbestos generally have a long latency with no or few symptoms. Then, when patients do become symptomatic, they present with advanced disease and a worse overall survival (about 13/15 months). The fibers from industrial production not only pose a substantial risk to workers, but also to their relatives and to the surrounding community. Modern targeted therapies that have shown benefit in other human tumors have thus far failed in MPM. Overall, MPM has been listed as orphan disease by the European Union. However, molecular high-throughput profiling is currently unveiling novel biomarkers and actionable targets. We here discuss the natural evolution, mainly focusing on the novel concept of molecular epidemiology. The application of innovative endpoints, quantification of genetic damages, and definition of genetic susceptibility are reviewed, with the ultimate goal to point out new tools for screening of exposed subject and for designing more efficient diagnostic and therapeutic strategies. Full article
Show Figures

Figure 1

Other

Open AccessBrief Report
Surgical Diagnosis of Malignant Pleural Mesothelioma: 20 Years’ Experience at a High-Volume Referral Center
J. Clin. Med. 2021, 10(9), 1973; https://doi.org/10.3390/jcm10091973 (registering DOI) - 04 May 2021
Viewed by 180
Abstract
Despite advances, malignant pleural mesothelioma (MPM) remains a challenging disease in terms of diagnosis, treatment, and overall management. Herein, we analyzed, in a large-scale single-center cohort, the characteristics and perioperative course of patients undergoing surgical diagnosis of MPM. We identified a total of [...] Read more.
Despite advances, malignant pleural mesothelioma (MPM) remains a challenging disease in terms of diagnosis, treatment, and overall management. Herein, we analyzed, in a large-scale single-center cohort, the characteristics and perioperative course of patients undergoing surgical diagnosis of MPM. We identified a total of 514 consecutive patients, 71.4% male and 28.6% female, with mean age 71.3 +/− 13.6 years. Most exhibited pleural, respiratory, or general symptoms and American Society of Anesthesiologists (ASA) score was ≥3 in 68.3% of cases. Thoracoscopy was the most frequent approach (92.0%) and short open thoracotomy was performed in the remaining patients. Pleurodesis was simultaneously performed in 74.3% of cases. Diagnostic failure led to redo surgery in 3.7% of patients. Non-epithelioid histology was found in 19.5% of MPMs and was significantly more frequent in right-sided MPM (p = 0.04), and in patients without history of cancer (p = 0.03), or pleural nodules at thoracoscopy (p = 0.01). Minor only or major complications occurred in respectively 7.8% and 3.6% of cases. They were more frequent in patients ≥ 70 years (p = 0.05) and Performance Status > 2 (p = 0.05). The mean hospital stay was 7.5 days. The 30-day and 90-day early mortality rates were 2.3% and 6.4%, respectively. Surgical diagnosis of MPM is a reliable procedure but is associated with significant morbidity and hospital-stay duration. Full article
Back to TopTop